A Study to Examine Patient Characteristics, Health Care Management and Health Outcomes of Hepatitis C Virus (HCV) Patients Treated With Simeprevir
A Prospective Observational Study to Examine Patient Characteristics, Health Care Management, and Effectiveness Among HCV Patients Treated With Simeprevir at Various Practice Settings
Studieoversikt
Status
Status
Forhold
Forhold
Intervensjon / Behandling
Intervensjon / Behandling
Detaljert beskrivelse
Studietype
Studietype
Registrering (Faktiske)
Registrering
Kontakter og plasseringer
Studiesteder
-
-
Arizona
-
Phoenix, Arizona, Forente stater
-
-
California
-
Bakersfield, California, Forente stater
-
Beverly Hills, California, Forente stater
-
Los Angeles, California, Forente stater
-
-
Florida
-
Daytona Beach, Florida, Forente stater
-
Deland, Florida, Forente stater
-
Miami, Florida, Forente stater
-
Tampa, Florida, Forente stater
-
West Palm Beach, Florida, Forente stater
-
-
Kentucky
-
Crestview Hills, Kentucky, Forente stater
-
-
Maryland
-
Baltimore, Maryland, Forente stater
-
-
Massachusetts
-
Springfield, Massachusetts, Forente stater
-
-
New Jersey
-
Newark, New Jersey, Forente stater
-
Vineland, New Jersey, Forente stater
-
-
New York
-
Brooklyn, New York, Forente stater
-
Flushing, New York, Forente stater
-
New York, New York, Forente stater
-
Ny, New York, Forente stater
-
-
North Carolina
-
Durham, North Carolina, Forente stater
-
Fayetteville, North Carolina, Forente stater
-
Rocky Mount, North Carolina, Forente stater
-
Statesville, North Carolina, Forente stater
-
Winston Salem, North Carolina, Forente stater
-
-
Ohio
-
Cincinnati, Ohio, Forente stater
-
-
Pennsylvania
-
Doylestown, Pennsylvania, Forente stater
-
Philadelphia, Pennsylvania, Forente stater
-
-
Tennessee
-
Nashville, Tennessee, Forente stater
-
-
Texas
-
Austin, Texas, Forente stater
-
Dallas, Texas, Forente stater
-
Fort Worth, Texas, Forente stater
-
Houston, Texas, Forente stater
-
-
Utah
-
Murray, Utah, Forente stater
-
-
Virginia
-
Norfolk, Virginia, Forente stater
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Prøvetakingsmetode
Studiepopulasjon
Beskrivelse
Inclusion Criteria:
- Patients who have genotype 1 chronic hepatitis C infection
- Hepatitis C virus (HCV) ribonucleic acid (RNA) test result above the limit of quantification before initiation of simeprevir-based therapy
- Health care provider decision to treat patient with a simeprevir-based therapy, inclusive of patients who have been treated with a simeprevir-based therapy for less than or equal to (<=) 28 days will be enrolled into the study
- Prior HCV treatment must be completed more than 3 months before initiation of simeprevir-based therapy
- In the opinion of the health care provider, the patient will attend routine standard of care visits, either at enrolled site or by virtual/telemedicine
Exclusion Criteria:
- Non-genotype 1 HCV infected patients
- Absolute contraindication to any component of prescribed HCV treatment per prescribing information
- Patient is currently enrolled in an interventional study
- Past use of an HCV direct-acting antiviral therapy
- Any investigational drug use within 30 days before initiation of simeprevir-based therapy
Studieplan
Hvordan er studiet utformet?
Designdetaljer
Antall grupper / kohorter
Kohorter og intervensjoner
Gruppe / KohortGruppe / Kohort |
Intervensjon / BehandlingIntervensjon / Behandling |
|---|---|
|
Hepatitis C virus infected patients receiving simeprevir
|
This is an observational study.
Patients receiving simeprevir (single capsule of 150 mg once daily) as prescribed by the health care provider will be observed.
|
Hva måler studien?
Primære resultatmål
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Number of Patients who Achieve Sustained Virologic Response(SVR)
Tidsramme: 12 weeks after the actual end of treatment (an expected average of up to 2 years)
|
SVR is defined as hepatitis C virus (HCV) ribonucleic acid (RNA) undetectable at least 12 weeks after the actual end of all HCV treatment.
Actual end of treatment will be determined by health care provider.
|
12 weeks after the actual end of treatment (an expected average of up to 2 years)
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Determination of Prognostic Factors of Virologic Response
Tidsramme: 12 weeks after the actual end of treatment (an expected average of up to 2 years)
|
Prognostic factors of virologic response includes patient and disease characteristics, treatment paradigm, Rapid Virologic Response (RVR), and select practice setting features.
Actual end of treatment will be determined by health care provider.
|
12 weeks after the actual end of treatment (an expected average of up to 2 years)
|
|
Total duration of therapy
Tidsramme: Up to actual end of treatment (an expected average of up to 2 years)
|
Actual end of treatment will be determined by health care provider.
|
Up to actual end of treatment (an expected average of up to 2 years)
|
|
Number of Patients who Discontinue Therapy by reason
Tidsramme: Up to actual end of treatment (an expected average of up to 2 years)
|
Actual end of treatment will be determined by health care provider.
|
Up to actual end of treatment (an expected average of up to 2 years)
|
|
Number of Patients who Achieve Rapid Virologic Response (RVR)
Tidsramme: Week 4
|
RVR is defined as undetectable hepatitis C virus (HCV) ribonucleic acid (RNA) at Week 4.
|
Week 4
|
|
Number of Patients who Achieve Sustained Virologic Response(SVR) Among Participants who Achieve Rapid Virologic Response (RVR)
Tidsramme: 12 weeks after the actual end of treatment (an expected average of up to 2 years)
|
SVR is defined as hepatitis C virus (HCV) ribonucleic acid (RNA) undetectable at least 12 weeks after the actual end of all HCV treatment.
RVR is defined as undetectable HCV RNA at Week 4. Actual end of treatment will be determined by health care provider.
Actual end of treatment will be determined by health care provider.
|
12 weeks after the actual end of treatment (an expected average of up to 2 years)
|
|
Number of Patients who Achieve Sustained Virologic Response(SVR) According to Patient Demographics, Baseline Disease Characteristics, Treatment Paradigm, and Select Practice Setting Features
Tidsramme: 12 weeks after the actual end of treatment (an expected average of up to 2 years)
|
Actual end of treatment will be determined by health care provider.
|
12 weeks after the actual end of treatment (an expected average of up to 2 years)
|
|
Number of Patients With On-treatment Virologic Failure
Tidsramme: Up to actual end of treatment (an expected average of up to 2 years)
|
On-treatment virologic failure is defined as a confirmed increase of >1 log10 IU/mL in hepatitis C virus (HCV) ribonucleic acid (RNA) level from the lowest level reached, or a confirmed HCV RNA level of >100 IU/mL in patients whose HCV RNA had previously been <25 IU/mL.
Actual end of treatment will be determined by health care provider.
|
Up to actual end of treatment (an expected average of up to 2 years)
|
|
Number of Patients With Viral Relapse
Tidsramme: Up to actual end of treatment (an expected average of up to 2 years)
|
Viral Relapse is defined as detectable hepatitis C virus (HCV) ribonucleic acid (RNA) after concluding treatment with undetectable HCV RNA.
Actual end of treatment will be determined by health care provider.
|
Up to actual end of treatment (an expected average of up to 2 years)
|
|
Number of Patients With Adverse Events by Grade and Causality
Tidsramme: Up to 24 weeks after the actual end of treatment (an expected average of up to 2 years)
|
Actual end of treatment will be determined by health care provider.
|
Up to 24 weeks after the actual end of treatment (an expected average of up to 2 years)
|
|
Number of Patients With Changes in Clinical Laboratory Parameters by Grade and Causality
Tidsramme: Up to 24 weeks after the actual end of treatment (an expected average of up to 2 years)
|
Actual end of treatment will be determined by health care provider.
|
Up to 24 weeks after the actual end of treatment (an expected average of up to 2 years)
|
|
Number of Patients With Adverse Event Determined to be Related to Simeprevir
Tidsramme: Up to 24 weeks after the actual end of treatment (an expected average of up to 2 years)
|
Actual end of treatment will be determined by health care provider.
|
Up to 24 weeks after the actual end of treatment (an expected average of up to 2 years)
|
|
Number of Patients With Serious Adverse Event
Tidsramme: Up to 24 weeks after the actual end of treatment (an expected average of up to 2 years)
|
Actual end of treatment will be determined by health care provider.
|
Up to 24 weeks after the actual end of treatment (an expected average of up to 2 years)
|
|
Number of Patients who Develop Mutations at the Time of Virologic Failure
Tidsramme: Up to actual end of treatment (an expected average of up to 2 years)
|
Actual end of treatment will be determined by health care provider.
|
Up to actual end of treatment (an expected average of up to 2 years)
|
Samarbeidspartnere og etterforskere
Sponsor
Sponsor
Studierekorddatoer
Studer hoveddatoer
Studiestart
Studiestart
Primær fullføring (Faktiske)
Primær fullføring
Studiet fullført (Faktiske)
Studiet fullført
Datoer for studieregistrering
Først innsendt
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Anslag)
Først lagt ut
Oppdateringer av studieposter
Sist oppdatering lagt ut (Anslag)
Sist oppdatering lagt ut
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
Andre studie-ID-numre
- CR101973
- TMC435HPC4003 (Annen identifikator: Janssen Scientific Affairs, LLC)
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .